Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Function Test Clear all
Withdrawn Phase 4 Interventional

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

NCT00636935
View directory record Official record
Conditions
Pneumocystis Carinii Pneumonia
Interventions
Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 30, 2026, 5:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity

NCT00528944
View directory record Official record
Conditions
Emphysema
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 81 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function

NCT01429584
View directory record Official record
Conditions
Diaphragm Paralysis
Interventions
interscalene nerve block with 0.25% bupivacaine, interscalene block with 0.125% bupivacaine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 30, 2026, 5:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pollutant Altered Allergic Responses

NCT00011440
View directory record Official record
Conditions
Allergic Rhinitis, Allergy
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2006 · Synced Oct 30, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise

NCT05025774
View directory record Official record
Conditions
Chronic Lung Disease, Chronic Obstructive Pulmonary Disease, Acute Lymphoblastic Leukemia, Heart Transplant
Interventions
Physical activity
Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
8 Years to 25 Years
Enrollment
90 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interaction Effects of Temperature and Ozone

NCT01981135
View directory record Official record
Conditions
Exposure to Environmental Pollution, Non-occupational
Interventions
Clean Air, Ozone
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

NCT02766608
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder
Interventions
BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
83
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 30, 2026, 5:32 AM EDT
Withdrawn Early Phase 1 Interventional

Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments

NCT04050852
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen Treatments
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 30, 2026, 5:32 AM EDT
Completed No phase listed Observational

Study of Lung Function in Children Who Have Undergone Bone Marrow Transplantation

NCT00009711
View directory record Official record
Conditions
Long-term Effects Secondary to Cancer Therapy in Children, Pulmonary Complications
Interventions
management of therapy complications
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 17 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 30, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis

NCT03839992
View directory record Official record
Conditions
Cystic Fibrosis in Children
Interventions
spirometry
Diagnostic Test
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
5 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Lakewood, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 30, 2026, 5:32 AM EDT
Withdrawn No phase listed Observational

Transfer Impedance in Cystic Fibrosis

NCT00743158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 30, 2026, 5:32 AM EDT
Not listed No phase listed Observational

Respiratory Monitoring System Safety and Performance Study

NCT05812378
View directory record Official record
Conditions
Pulmonary Function Test, Tidal Volume, Respiratory Rate, Ventilators, Breathing Sounds
Interventions
Not listed
Lead sponsor
RTM Vital Signs, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Not applicable Interventional

The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations

NCT01582958
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Osteopathic Manipulative Treatment (OMT), sham omt
Procedure · Other
Lead sponsor
Michigan State University
Other
Eligibility
49 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 30, 2026, 5:32 AM EDT
Not yet recruiting Not applicable Interventional

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

NCT07414810
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
micro Sweat Test Patch (mSTP), Sweat Testing using SOC
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Weeks to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning

NCT00596310
View directory record Official record
Conditions
Lung Cancer
Interventions
CT
Other
Lead sponsor
Susanne Arnold
Other
Eligibility
55 Years to 75 Years
Enrollment
531 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2020
U.S. locations
4
States / cities
Hazard, Kentucky • Morehead, Kentucky • Prestonsburg, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

NCT01691482
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol/salbutamol, Ipratropium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 30, 2026, 5:32 AM EDT
Completed No phase listed Observational

Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis

NCT01343524
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
4 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 30, 2026, 5:32 AM EDT
Not listed No phase listed Observational

The Evaluation of Hemostasis in Hospitalized COVID-19 Patients

NCT04493307
View directory record Official record
Conditions
COVID-19
Interventions
Phlebotomy
Diagnostic Test
Lead sponsor
LifeBridge Health
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739
View directory record Official record
Conditions
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 30, 2026, 5:32 AM EDT